18 July 2014 | News | By BioSpectrum Bureau
GVK Bio launches Clinogent
The launch of clinogent is a part of GVK BIO's growth plan in taking the organisation to the next level
In a bid to race ahead to be among the top three Asian clinical research organizations in the next five years, India's Hyderabad-based contract research company GVK Biosciences (GVK BIO) has unveiled a new brand.
"GVK BIO is well-known as a discovery services company. Today in our estimate we are No 4 or No 5 in the country in clinical research and clinical development. Our goal is to be in top three in Asia in the next five years through the new brand Clinogent," Mr Manni Kantipudi, Chief Executive of GVK Biosciences said at the official announcement.
The firm unveiled a new brand, 'Clinogent', in the clinical development industry to offer integrated clinical trial outsourcing solutions. "The launch of the new brand, Clinogent is part of GVK BIO's growth plan in taking the organization to the next level and creating a benchmark in the industry," he added.
Ahead of its growth plans, the firm also plans to increase its bed capacity by 50 at its Ahmedabad facility. This would help in carrying out clinical trials and starting an analytical laboratory in the next three months.
"We are looking to expand our capacity. We have space in Ahmedabad facility. We are starting with a bio-analytical laboratory in Ahmedabad and add another 50 beds in Ahmedabad," Mr Chetan Tamhankar, Senior Vice-President (Clinical Development), GVK BIO said at the announcement. The new addition of beds will be to the company's existing facilities in Hyderabad and Ahmedabad.
With its new brand, the company is hoping to further strengthen its operational expertise and technology to evolve into a specialist and comprehensive service offering entity in the clinical research and development market, Mr Kantipudi explained.
He added, "Clinogent will be a clinical development service provider, which will be able to address the clinical needs of both innovator bio-pharmaceutical and generics companies world-wide."